Inovio Pharmaceuticals, Inc. (INO) Stock Rating Reaffirmed by Maxim Group
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)‘s stock had its “buy” rating reissued by investment analysts at Maxim Group in a research note issued on Tuesday. They presently have a $12.00 price target on the biopharmaceutical company’s stock. Maxim Group’s target price points to a potential upside of 101.01% from the stock’s current price.
Other equities analysts have also recently issued research reports about the stock. Piper Jaffray Companies upgraded shares of Inovio Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $14.00 price target on the stock in a research report on Thursday, June 8th. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 3rd. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a research report on Tuesday, July 11th. BidaskClub upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 9th. Finally, Aegis boosted their price target on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, May 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $19.80.
Shares of Inovio Pharmaceuticals (NASDAQ INO) traded up 0.84% during mid-day trading on Tuesday, hitting $5.97. The stock had a trading volume of 4,351,989 shares. The firm’s market capitalization is $538.66 million. The stock’s 50-day moving average is $5.70 and its 200 day moving average is $6.67. Inovio Pharmaceuticals has a 1-year low of $5.28 and a 1-year high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The company had revenue of $20.41 million for the quarter, compared to analysts’ expectations of $16.29 million. During the same quarter in the previous year, the company earned ($0.26) earnings per share. Inovio Pharmaceuticals’s quarterly revenue was up 229.2% on a year-over-year basis. Equities research analysts predict that Inovio Pharmaceuticals will post ($0.92) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/17/inovio-pharmaceuticals-inc-ino-stock-rating-reaffirmed-by-maxim-group.html.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Inovio Pharmaceuticals by 4.2% in the second quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock worth $25,301,000 after purchasing an additional 129,164 shares during the period. Wasatch Advisors Inc. grew its holdings in Inovio Pharmaceuticals by 43.6% in the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after purchasing an additional 793,306 shares during the period. Northern Trust Corp grew its holdings in Inovio Pharmaceuticals by 2.8% in the second quarter. Northern Trust Corp now owns 896,472 shares of the biopharmaceutical company’s stock worth $7,028,000 after purchasing an additional 24,366 shares during the period. Geode Capital Management LLC grew its holdings in Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock worth $3,708,000 after purchasing an additional 62,045 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after purchasing an additional 11,765 shares during the period. Institutional investors and hedge funds own 24.83% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.